Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Single-Arm Multicenter Study to Access Efficacy and Safety of P1101 in Chinese Polycythemia Vera Patients Who Are Intolerant or Resistance to Hydroxyurea

NCT05485948 is registered in ClinicalTrials.gov with PharmaEssentia as lead sponsor.

NCT NCT05485948
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05485948 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Single-Arm Multicenter Study to Access Efficacy and Safety of P1101 in Chinese Polycythemia Vera Patients Who Are Intolerant or Resistance to Hydroxyurea
Lead sponsor
PharmaEssentia
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 8, 2021
Completion date
July 31, 2027
Enrollment
49 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

polycythemia vera